COVID-19 Vaccines - 2025/2026

Eligible Fall 2025 AND Spring 2026: Individuals listed below should receive a dose of COVID-19 vaccine, along with a flu shot, as soon as the vaccine is available to them. Those listed below are also eligible for an additional dose in the spring of 2026.

• individuals 6 months of age and older with underlying medical conditions, including children with complex health needs; a list of these complex needs is available from the Government of Canada website
• adults 65 years of age and older
  
  • National Advisory Committee on Immunization (NACI) recommends that those 80 years and older should receive an additional dose of vaccine while those 65 to 79 years of age may receive an additional dose of vaccine in the spring.
• adult residents of long-term care homes and other congregate living settings for seniors
• individuals 6 months of age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment); see the list below
• individuals 55 years and older who identify as First Nations, Inuit, or Métis and their non-Indigenous household members who are 55 years and older

Eligible Fall 2025 and Spring 2026: Those who are considered moderately to severely immunocompromised are recommended to get their next dose, along with a flu shot, as soon as the vaccine is available to them. Those listed below are also eligible for an additional dose in the spring of 2026.

• solid tumour or hematologic malignancies or treatments for these conditions
• solid-organ transplant and taking immunosuppressive therapy
• hematopoietic stem cell transplant (HSCT) (within 2 years of transplantation or taking immunosuppression therapy)
• immunocompromised due to chimeric antigen receptor (CAR) T cell therapy targeting lymphocytes
• moderate to severe primary immunodeficiency with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation
• HIV with AIDS-defining illness or TB diagnosis in last 12 months before starting vaccine series, or severe immune compromise with CD4 ‹ 200 cells/µL or CD4<15%, or without HIV viral suppression
• recent treatment with the following categories of immunosuppressive therapies:
  
  • anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22)
  • high-dose systemic corticosteroids
  • alkylating agents
  • antimetabolites
  • tumor-necrosis factor (TNF) inhibitors
  • other biologic agents that are significantly immunosuppressive
• chronic kidney disease on dialysis

Contact your health-care provider if you have received any of the following since your most recent COVID-19 vaccination(s) as you may be recommended to be re-vaccinated due to loss of immunity following transplant or therapy:

• a hematopoietic stem cell transplant
• hematopoietic cell transplant (autologous or allogeneic)
• a (CAR)-T-cell therapy

Eligible Fall 2025: Other priority groups are also recommended to receive their next dose, along with a flu shot, as soon as it is available.

The other priority groups include:

• children 6 months to 4 years of age
• individuals with significant exposure to birds or mammals through interactions with birds or mammals (such as poultry, livestock, slaughterhouse and processing plant workers, wildlife officers/researchers, and veterinarians)
• those at increased risk of exposure or severe outcomes including:
  
  • residents in long-term care homes and other congregate living settings who are aged 17 years and under
  • pregnant individuals
  • individuals from First Nations, Métis and Inuit communities who are aged 54 years and under
  • members of racialized and other equity-denied communities
  • health-care workers and other care providers in facilities and community settings as outlined in the guidance from the National Advisory Committee on Immunization (NACI)